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Sources from Ireland, America, Serbia and worldwide agree that cannabis is the most popular and most commonly 
used illicit substance worldwide [1-3]. Internationally, there has been a gradual shift from prohibition to medicinal 
uses [4]. There have been many cases described in the literature of patients suffering from chronic conditions such 
as cancer, arthritis, Parkinson’s disease, multiple sclerosis, Human Immunodeficiency Virus infection (HIV), 
epilepsy, migraine, autoimmune disease, and psychiatric disorders self-medicating with cannabis for its 
therapeutic effects [5-7]. In addition, a systematic review and meta-analysis of 79 trials involving 6462 patients 
concluded that there was moderate quality evidence supporting the medicinal use of certain cannabinoids [8]. 
There was also low quality evidence supporting the use of cannabinoids for nausea and vomiting due to 
chemotherapy, sleep disorders and Tourette’s syndrome [8]. More recently cannabidiol has been shown to reduce 
seizure frequency in Dravet syndrome [9]. Cannabis contains several active substances. One which leads to 
addiction and is regarded as most toxic is tetrahydrocannabinol (THC)[10] However other compounds in cannabis, 
such as cannabidiol, appear to have therapeutic effect but with little of the addictive psychotropic effects.  
 There are two Food and Drugs Authority (FDA) approved cannabinoids available in the United States 
for treatment of nausea and vomiting associated with chemotherapy, namely dronabinol (Marinol) and nabilone 
(Cesamet) [11]. Another cannabis extract, nabiximols (Sativex), is in phase 3 clinical trials for use in multiple 
sclerosis and neuropathic pain linked to cancer, and is already available in Europe and Canada [11]. 
 As with any drug with psychoactive properties that is used to treat chronic disease, there is always the 
risk of developing addiction. The safety of cannabis use as a medical treatment is not well researched and there is 
insufficient information on its long term side effects [2]. Other drugs with psychoactive properties and addiction 
potential such as morphine are routinely used for a number of conditions such as cancer related pain [12]. While  
there are concerns among healthcare professionals over the possibility of addiction, these are dealt with by limiting 
the drug’s availability by making it subject to the Misuse of Drugs Act (MDA) [12]. This results in close 
supervision of patients who are prescribed such drugs [13]. In our opinion, cannabinoids with proven therapeutic 
efficacy should be made available but subject to other legislation such as such as the Controlled Substances Act 
(USA) [14] and the Misuse of Drugs Act in the UK [15]. These could then be tested scientifically under controlled 
conditions and their risk/benefit balance defined rigorously. Funding from a neutral source such as the Health 
Research Board would help ensure the rigour of this research and the acceptability of the findings internationally. 
Only then can the true place of cannabinoids in medical therapeutics be determined. 
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